Eagle Pharmaceuticals market cap is $615 m, and annual revenue was $195.89 m in FY 2019

Eagle Pharmaceuticals Cash, 30-Sept-202089.7 M

Eagle Pharmaceuticals EV563.2 M

Eagle Pharmaceuticals revenue was $195.89 m in FY, 2019

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Revenue | 19.1m | 66.2m | 189.5m | 236.7m | 213.3m | 195.9m |

| 247% | 186% | ||||

## Cost of goods sold | 11.7m | 15.6m | 34.3m | 33.7m | 42.4m | 47.9m |

## Gross profit | 7.4m | 50.6m | 155.2m | 203.0m | 170.9m | 148.0m |

| 39% | 76% | 82% | 86% | 80% | 76% |

## R&D expense | 16.8m | 27.9m | 30.3m | 32.6m | 44.4m | 36.8m |

## General and administrative expense | 9.3m | 20.2m | 52.3m | 71.4m | 60.5m | 76.4m |

## Operating expense total | 26.1m | 48.0m | 101.8m | 129.0m | 134.3m | 126.2m |

## EBIT | (18.8m) | 2.6m | 53.4m | 74.0m | 36.6m | 21.8m |

| (98%) | 4% | 28% | 31% | 17% | 11% |

## Interest expense | 76.0k | 1.0m | 2.6m | 183.0k | ||

## Interest income | 31.0k | 25.0k | 84.0k | 91.0k | 158.0k | 2.2m |

## Pre tax profit | (19.3m) | 2.6m | 53.4m | 72.9m | 34.0m | 22.0m |

## Income tax expense | (1.3m) | 3.0k | (28.0m) | 21.0m | 2.1m | 7.7m |

## Net Income | (18.0m) | 2.6m | 81.5m | 51.9m | 31.9m | 14.3m |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Cash | 22.7m | 79.1m | 52.8m | 114.7m | 78.8m | 109.8m |

## Accounts Receivable | 7.3m | 26.3m | 42.2m | 53.8m | 66.5m | 48.0m |

## Prepaid Expenses | 1.7m | 15.1m | 10.3m | 15.1m | ||

## Inventories | 1.3m | 15.0m | 11.4m | 5.1m | 8.3m | 6.6m |

## Current Assets | 53.0m | 122.3m | 109.1m | 188.7m | 163.8m | 179.4m |

## PP&E | 344.0k | 2.2m | 3.3m | 6.8m | 2.4m | 2.2m |

## Goodwill | 39.7m | 39.7m | 39.7m | 39.7m | ||

## Total Assets | 53.4m | 124.6m | 214.3m | 270.1m | 238.6m | 254.6m |

## Accounts Payable | 4.1m | 3.9m | 14.7m | 12.0m | 9.9m | 5.5m |

## Short-term debt | 4.9m | 6.3m | 5.0m | |||

## Current Liabilities | 20.3m | 34.3m | 41.0m | 47.3m | 39.7m | 38.8m |

## Long-term debt | 42.9m | 38.2m | 36.6m | |||

## Total Debt | 4.9m | 6.3m | 41.6m | |||

## Total Liabilities | 75.4m | |||||

## Common Stock | 14.0k | 16.0k | 17.0k | 17.0k | ||

## Preferred Stock | ||||||

## Additional Paid-in Capital | 137.3m | 197.4m | 213.9m | 233.6m | 256.5m | 278.5m |

## Retained Earnings | (104.2m) | (107.1m) | (25.7m) | 26.3m | 58.2m | 72.5m |

## Total Equity | 33.1m | 90.3m | 151.2m | 179.1m | 160.8m | 179.2m |

## Debt to Equity Ratio | 0 x | 0 x | ||||

## Debt to Assets Ratio | 0 x | 0 x | ||||

## Financial Leverage | 1.6 x | 1.4 x | 1.4 x | 1.5 x | 1.5 x | 1.4 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Net Income | (18.0m) | 2.6m | 81.5m | 51.9m | 31.9m | 14.3m |

## Depreciation and Amortization | 13.0k | 3.7m | 3.7m | 4.7m | ||

## Accounts Receivable | (2.2m) | (14.3m) | (15.9m) | (11.6m) | (12.7m) | 18.5m |

## Inventories | (1.3m) | (13.8m) | 12.3m | (2.4m) | (5.6m) | 1.7m |

## Accounts Payable | 2.9m | 356.0k | 10.7m | (8.5m) | (2.1m) | (4.5m) |

## Cash From Operating Activities | (13.8m) | (9.7m) | 53.2m | 58.9m | 52.4m | 56.0m |

## Purchases of PP&E | (46.0k) | (1.9m) | (1.6m) | (4.4m) | (133.0k) | (777.0k) |

## Cash From Investing Activities | (20.0m) | (1.9m) | (45.8m) | (5.2m) | (133.0k) | (777.0k) |

## Long-term Borrowings | (1.2m) | (3.7m) | (6.0m) | |||

## Cash From Financing Activities | 46.2m | 55.8m | (33.7m) | 8.1m | (88.1m) | (24.2m) |

## Net Change in Cash | 61.8m | (35.9m) | 31.0m | |||

## Interest Paid | 1.0k | 651.0k | 2.1m | 2.5m | ||

## Income Taxes Paid | 10.5m | 2.3m | 6.7m |

USD | Q2, 2014 |
---|---|

## Financial Leverage | 1.4 x |